CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop a novel immunotherapy for relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) by targeting specific antigens unique to T-cell lymphoblasts. The approach seeks to provide a safer and more effective treatment option compared to current therapies.
R/R T-ALL remains a major clinical challenge.
Despite improved survival rates thanks to intensive chemotherapy regimens, event-free (EFS) and overall (OS) survival remains <70% and R/R T-ALL has a particularly poor outcome.
There are currently no potential curative options for R/R T-ALL beyond hematopoietic stem cell transplantation (HSCT) and conventional chemotherapy, which is linked to large trade-offs in toxicities.
Sadly, >90% of patients with R/R T-ALL/LL ultimately die.
Strategies targeti…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
INSTITUT JOSEP CARRERAS - CERCA
Spain, Badalona
Type: Research institute
Activity type: Research Organisations
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
